N/A N=103 Twinrix Pregnancy Registry
Hepatitis
Primary: Number of Outcomes From Pregnancies With Reported Exposure Within 28 Days of Last Menstrual Period — 0; 0; 0; 0 Pregnancy Outcomes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau]) — 103.978; 81.715 Microgram *…
N/A N=55 Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
Nausea · Emesis
Primary: Number of Participants With Nausea 1 Hour After Post-anesthesia Care Unit (PACU) Admission — 1; 0; 1; 14 Participants
Phase 2 N=102 Darbepoetin Administration to Preterm Infants
Infant, Newborn
Primary: Number of Transfusions During Hospitalization — 1.2; 1.2; 2.4 number of transfusions
N/A N=178 Endurant Stent Graft System Post Approval Study (ENGAGE PAS)
Aortic Aneurysm, Abdominal
Primary: Freedom From Aneurysm-related Mortality Rate (ARM) at 5 Years (1826 Days) — 0.989 Proportion of Surviving
N/A N=79 Prospective Study on a Novel Port-site Closure Device (EZ Close): Effectiveness and Comparison With Carter-Thomason
Surgical Port Site Hernia
Primary: Time Taken to Complete Closure — 36.8; 48.9 seconds
N/A N=35 ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System
Atherosclerosis · Peripheral Vascular Disease · Claudication
Primary: Device Success — 100.0 percentage of devices
Phase 2 N=50 Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Leukemia · Lymphoma · Myeloma
Primary: Maximum Tolerated Dose — 6800 mmol-min/L
N/A N=540 Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
Renal Insufficiency
Primary: Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem — 0 Participants
N/A N=55 Distal Renal Denervation
Hypertension, Resistant to Conventional Therapy
Primary: Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM) — 21.1; 10.3 mmHg — p=0.045
Phase 1 N=14 Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers
Iron-refractory, Iron-deficiency Anemia (IRIDA)
Primary: Pharmacokinetics (PK) of Total Iron From Triferic Administered Orally in Adult Healthy Patients: Cmax — 140; 62.0; 32.4; 51.9 microgram/deciliter
N/A N=2,443 Person-Centered Versus Measurement-Based Care in Mental Health
Schizophrenia · Bipolar Disorder · Major Depression
Primary: Patient Experience of Medication Treatment (PEMM) — 3.009; 3.007; 2.6; 3.09 Units on a scale — p=<0.0001
Phase 3 N=2,095 Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
Infections, Meningococcal · Meningococcal Vaccines
Primary: Percentage of Subjects With Serum Bactericidal Assay Using Baby Rabbit Complement Against Meningococcal Serogroups A, W-135 and Y (rSBA-MenA, rSBA-MenW-135 and rSBA-Y)…
Phase 1 N=57 An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 3; 2 participants
N/A N=2,589 Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Herpes Zoster Disease
Primary: Number of Participants Who Received the Herpes Zoster Vaccine — 500; 2089 Participants